🇺🇸 FDA
Pipeline program

Glasdegib

20195533

Phase 2 small_molecule active

Quick answer

Glasdegib for Acute Myelogenous Leukemia (AML) Due to Therapy is a Phase 2 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Jazz Pharmaceuticals plc
Indication
Acute Myelogenous Leukemia (AML) Due to Therapy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials